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Abstract 
Background: Progression rates from initial HIV‑1 infection to advanced AIDS vary significantly among infected individu‑
als. A distinct subgroup of HIV‑1‑infected individuals—termed viremic non‑progressors (VNP) or controllers—do not 
seem to progress to AIDS, maintaining high CD4+ T cell counts despite high levels of viremia for many years. Several 
studies have evaluated multiple host factors, including immune activation, trying to elucidate the atypical HIV‑1 disease 
progression in these patients; however, limited work has been done to characterize viral factors in viremic controllers.
Methods: We analyzed HIV‑1 isolates from three VNP individuals and compared the replicative fitness, near full‑
length HIV‑1 genomes and intra‑patient HIV‑1 genetic diversity with viruses from three typical (TP) and one rapid (RP) 
progressor individuals.
Results: Viremic non‑progressors and typical patients were infected for >10 years (range 10–17 years), with a mean 
CD4+ T‑cell count of 472 cells/mm3 (442–529) and 400 cells/mm3 (126–789), respectively. VNP individuals had a less 
marked decline in CD4+ cells (mean −0.56, range −0.4 to −0.7 CD4+/month) than TP patients (mean −10.3, −8.2 
to −13.1 CD4+/month). Interestingly, VNP individuals carried viruses with impaired replicative fitness, compared to 
HIV‑1 isolates from the TP and RP patients (p < 0.05, 95% CI). Although analyses of the near full‑length HIV‑1 genomes 
showed no clear patterns of single‑nucleotide polymorphisms (SNP) that could explain the decrease in replicative fit‑
ness, both the number of SNPs and HIV‑1 population diversity correlated inversely with the replication capacity of the 
viruses (r = −0.956 and r = −0.878, p < 0.01, respectively).
Conclusion: It is likely that complex multifactorial parameters govern HIV‑1 disease progression in each individual, 
starting with the infecting virus (phenotype, load, and quasispecies diversity) and the intrinsic ability of the host to 
respond to the infection. Here we analyzed a subset of viremic controller patients and demonstrated that similar to 
the phenomenon observed in patients with a discordant response to antiretroviral therapy (i.e., high CD4+ cell counts 
with detectable plasma HIV‑1 RNA load), reduced viral replicative fitness seems to be linked to slow disease progres‑
sion in these antiretroviral‑naïve individuals.
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Background
Infection with human immunodeficiency virus type 
1 (HIV-1)—in the absence of antiretroviral therapy—
usually follows a well-defined path of virological and 
immunological changes; however, progression rates to 
advanced AIDS vary significantly among infected indi-
viduals [1, 2]. Based on plasma HIV-1 RNA (viral) load, 
CD4+ T-cell counts, and symptomatic or asymptomatic 
HIV-1 infection adult patients have been classified into 
four groups: (i) rapid progressors (RP), (ii) typical pro-
gressors (TP), and two groups of long-term non-progres-
sors (LTNP) namely (iii) elite controllers and (iv) viremic 
controllers [3, 4]. Among the latter, a rare subgroup of 
HIV-1-infected individuals has been described who do 
not seem to progress to AIDS, maintaining high CD4+ 
T-cell counts despite high levels of viremia (i.e., over 2000 
HIV-1 copies RNA/ml of plasma) for many years, also 
called viremic non-progressors (VNPs) [5–8].
Multiple studies have tried to associate these differ-
ences in HIV-1 disease progression with a multitude 
of host (HIV-1-specific immune response and genetic 
markers) and viral factors [9–13]. Among the immuno-
logical factors, strong HIV-1-specific cytotoxic T cell 
(CTL) responses have been shown to control HIV-1 
infection right after transmission, perhaps determining 
viral set point in chronic stages of infection, which may 
help reduce the rate of HIV-1 disease progression [14, 
15]. Similarly, a series of host genetic factors that seem 
to influence HIV-1 progression rates have been well 
described, including human leukocyte antigen (HLA) 
class I alleles such as HLA-B*27 and HLA-B*57 [16, 17] 
and a 32  bp deletion in the CCR5 chemokine receptor 
gene [18–22]. On the other hand, the impact of restric-
tion cellular factors like APOBEC3, TRIM5α, tetherin, 
and SAMHD1 on HIV-1 progression is still debated [10, 
23]. Altogether, it has been long recognized that immune 
activation is one of the major contributors to HIV-1 dis-
ease and pathogenesis [6, 24–27].
Viral factors—such as impaired HIV-1 replicative fit-
ness—have been associated with slow or limited HIV-1 
disease progression [11, 28–31], particularly in patients 
infected with heavily mutated drug resistant viruses [28, 
30, 32–35]. High fitness of transmitted HIV-1 has been 
related to rapid disease progression [36], while some 
individuals carrying viruses with decreased replication 
capacity during acute/early infection have been classi-
fied as HIV controllers [37]. Although isolating replica-
tion competent HIV-1 strains from elite controllers has 
been difficult, two studies failed to identify any major 
defect on the replication ability of these viruses [38, 39]. 
In contrast, recombinant viruses constructed with HIV-1 
gag, pol, and/or env genes from elite controllers exhibited 
reduced replication capacity compared to recombinant 
viruses constructed from typical progressors [40–42]. On 
the other hand, very limited information about the repli-
cative fitness of viruses infecting viremic non-progressor 
individuals is currently available [6, 43]. If a decrease in 
HIV-1 replicative fitness is associated with slower/no 
disease progression, what is causing the virus to have 
this reduced replication capacity—in the absence of drug 
resistance mutations—in a certain number of non-pro-
gressor patients?
To date, no common pattern or polymorphism(s) 
shared among HIV-1 variants infecting non-progres-
sor individuals have been clearly defined. Several stud-
ies have described changes in the LTR, e.g., in the Sp1 
binding site [44] or large deletions [11, 45] that could be 
associated with slow disease progression. Detrimental 
mutations in Gag have been associated with viral attenu-
ation [46, 47], which seem to play an important role in 
HIV-1 disease [48, 49]. Significant replicative fitness 
loss was observed in recombinant viruses encoding pol 
genes with mutations affecting HLA-A, but surprisingly 
not HLA-B, binding [50], although the most attenuated 
viruses were those constructed from HIV-1 elite control-
lers expressing HLA-B*57 and HLA-B*51 [40]. Changes 
in the V2 region of gp120 [51, 52] and a single amino 
acid deletion in gp41 [53] in the env gene have also been 
associated with slow disease progression. However, most 
of the changes in the HIV-1 genome linked to altered 
pathogenesis have been identified in accessory genes. 
Single amino acid substitutions [54, 55] and large dele-
tions [56, 57] in Nef have been associated with a decrease 
in replicative fitness and slow disease progression. Muta-
tions at positions 72 and 77 in Vpr, disrupting the viral 
protein function, were frequently detected in non-pro-
gressors [58, 59]. Finally, single or large insertions in Vpu 
[60] and amino acid substitutions in Vif [61, 62] have also 
been associated with non-progression in HIV-1 disease.
In this pilot study we quantified the replicative fitness 
of HIV-1 isolates obtained from extremely rare viremic 
non-progressor HIV-infected individuals and compared 
them to the fitness of those from patients with typical 
or rapid disease progression. Using deep sequencing we 
analyzed the full-length HIV-1 genomes and determined 
intrapatient HIV-1 diversity to investigate if these viral 
factors could be contributing to the maintenance of stable 
CD4+ T-cell counts despite persistence viremia for more 
than 10 years, in the absence of antiretroviral treatment.
Methods
Clinical samples
Blood samples were obtained during routine patient 
monitoring from a well-characterized cohort of HIV-
infected individuals at the Special Immunology Unite 
(SIU) at Case Western Reserve University/University 
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Hospitals Cleveland Medical Center (CWRU/UHCMC), 
with the written informed consent. Seven subjects were 
selected and grouped based on the following definitions: 
(i) viremic non-progressors (VNP, n =  3) corresponding 
to patients serologically proven to be HIV-1-infected for 
at least 10  years, CD4+ T-cell decline of  <45 cells/mm3 
per year and repeated plasma HIV-1 RNA load  >1000 
copies/ml in the absence of antiretroviral therapy; (ii) 
typical progressors (TP, n = 3) corresponding to patients 
serologically proven to be HIV-1-infected for at least 
10  years, CD4+ T-cell decline of  >75 cells/mm3 per 
year and repeated plasma HIV-1 RNA load  >1000 cop-
ies/ml in the absence of antiretroviral therapy; and (iii) 
rapid progressor (RP, n =  1) corresponding to a patient 
serologically proven to be HIV-1-infected for at least 
5  years, CD4+ T-cell decline of  >77 cells/mm3 per year 
and repeated plasma HIV-1 RNA load >10,000 copies/ml 
in the absence of antiretroviral therapy. In the case of the 
VNP and TP patients, CD4+ T-cell numbers and plasma 
HIV-1 load levels were monitored for a minimum of 
30 months (18 months for the RP patient) with at least 10 
determinations over this period. Demographics, clinical 
and virological characteristics are summarized in Table 1.
Cells and viruses
Peripheral blood mononuclear cells (PBMC), obtained 
from HIV-seronegative donors, were stimulated with 
2.5  µg/ml of phytohemagglutinin (PHA; Gibco BRL) 
and maintained in RPMI 1640/2 mM l-glutamine media 
(Cellgro; Mediatech, Herndon, VA) supplemented 
with 10% fetal bovine serum (Cellgro), 10  mM HEPES 
buffer (N-2-hydroxyethylpiperazine-N-2-ethanesulfonic 
acid; Cellgro), 1  ng/ml of interleukin-2 (IL-2) (Gibco, 
BRL), 100 U of penicillin/m (Cellgro) and 100  μg of 
Table 1 Demographic, clinical and virological parameters
R5 CCR5-tropic virus, D/M dual- or mixed-tropic virus
a  Age at the time of sampling
b  M male
c  MSM men who have sex with men
d  Years since first HIV-seropositive test to time of blood sample collection for this study
e  Number of months that the patient had been monitored up to the blood sample collection date
f  CD4+ T-cell count (cells/mm3) and HIV-1 RNA plasma load (log10 copies/ml) at the time the blood sample was obtained
g  Mean and range CD4+ T-cell count and HIV-1 RNA plasma load values determined during the clinical follow up time, to the time of blood sample collection for this 
study and prior to the initiation of antiretroviral treatment
h  Rate of CD4+ T-cell count decline (slope) calculated as cells/mm3 per month, using all CD4+ cell measurements available at the time the blood sample was obtained
i  HIV-1 subtype determined using the near full-length HIV-1 genome consensus sequences with the Recombinant Identification Program (RIP) from the Los Alamos 
HIV Sequence Database (https://www.hiv.lanl.gov/content/sequence/RIP/RIP.html) [76]
j  HIV-1 coreceptor tropism determined using sequencing reads corresponding to the V3 region of gp120, env gene with the DEEPGEN™HIV Software Tool Suite [70]
Patient ID Viremic non-progressors (VNP) Typical progressors (TP) Rapid progressor (RP)
VNP-1 VNP-2 VNP-3 TP-1 TP-2 TP-3 RP
Demographics
 Agea 44 50 42 40 43 38 30
 Sexb M M M M M M M
 Race Black Caucasian Black Caucasian Black Black Black
 Risk Factorc MSM Unknown MSM MSM MSM MSM MSM
 Years HIV+d 14 17 10 14 15 12 5
 Follow up (months)e 84 37 123 35 19 31 18
CD4+ (cells/mm3)
 CD4+ countf 563 443 479 386 361 126 11
 Mean CD4+ countg 529 445 442 483 457 293 57
 Range CD4+ countg 372–711 316–608 280–814 220–789 361–645 126–511 11–124
 Slope CD4+ counth −0.6 −0.7 −0.4 −9.6 −8.2 −13.1 −4.7
HIV‑1 RNA (log 10 copies/ml)
 HIV‑1 RNAf 5.46 4.90 4.70 4.41 4.27 4.49 4.64
 Mean HIV‑1 RNAg 4.68 4.91 4.31 4.23 4.45 4.67 4.49
 Range HIV‑1 RNAg 3.61–5.45 4.27–5.08 3.62–4.71 3.89–4.62 4.28–4.62 3.90–4.90 4.09–4.66
Virus characteristics
 HIV‑1 subtypei B B B B B B B
 HIV‑1 coreceptor tropismj R5 R5 R5 R5 R5 R5 D/M
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streptomycin/ml (Cellgro), for three days before infec-
tion with HIV-1 [28]. HIV-1 isolates were obtained from 
all seven patients by co-cultivating their PBMCs with 
PBMCs from HIV-seronegative donors as described [28]. 
Three primary HIV-1 isolates (HIV-1A-92UG029, HIV-1B-
92US076, and HIV-1AE-CMU06) were obtained from the AIDS 
Research and Reference Reagent Program and propa-
gated in PHA-stimulated, IL-2-treated PBMCs. Tissue 
culture dose for 50% infectivity (TCID50) was determined 
for each virus in PBMCs in triplicate with serially diluted 
stocks, based on the reverse transcriptase (RT) activity in 
culture supernatants on day 7 of culture, using the Reed 
and Muench method [63]. Viral titers were expressed as 
infectious units per milliliter (IU/ml).
HIV-1 replicative fitness determination using viral growth 
kinetics analysis
The ability of the seven patient-derived HIV-1 isolates, 
plus the primary wild-type HIV-1B-92US076 isolate used 
as control, to replicate in the absence of drug pressure 
was determined by measuring viral growth kinetics as 
described [64, 65]. Briefly, 1  ×  106 PHA-stimulated, 
IL-2-treated PBMCs were infected at a multiplicity of 
infection (MOI) of 0.001  IU/cell in 1  ml of RPMI 1640 
medium and incubated for 2 h at 37 °C in 5% CO2. HIV-
infected cells were then washed twice with 1x PBS and 
split to be cultured in triplicate wells of a 96-well plate 
(1 × 105 cells/well). Fresh PHA-stimulated, IL-2–treated 
PBMCs (5 ×  104 cells) were added to each well at days 
5 and 10 post-infection. Reverse transcriptase activity 
in the culture supernatant was assayed on days 0, 4, 6, 8, 
11, and 14 post-infection as described [28]. Viral replica-
tion was quantified using the slope of the growth curves 
and performing linear regression analysis derived from 
the equation log(y) = mt + log(h), where y is virus quan-
tity (cpm), t is time in days, and h is the y-intercept (day 
0). All slope values for each virus were used to calculate 
means and standard deviations. Differences in the mean 
values were evaluated using a one way analysis of vari-
ance test and the significance difference from the control 
HIV-1B-92US076 calculated using the Bonferroni’s Multi-
ple Comparison Test (GraphPad Prism v.6.0b, GraphPad 
Software).
HIV-1 replicative fitness determination using growth 
competition experiments
Dual infection/competition experiments were carried 
out as previously described [28, 35, 66, 67]. Briefly, each 
query virus (patient-derived subtype B HIV-1 isolates 
and the HIV-1B-92US076 control) was competed against 
two different non-subtype B HIV-1 control strains (HIV-
1A-92UG029 and HIV-1AE-CMU06) in a 1:1 initial proportion 
using an MOI of 0.001 IU/cell to infected 1 × 106 PBMCs 
for 2  h at 37  °C and 5% CO2. Cells were subsequently 
washed twice with 1× PBS and cultured in a 24-well 
plate. Cell-free supernatant and cells were harvested at 
day 10 and stored at −80 °C for subsequent analysis. The 
final proportions of the two viruses in each competition 
were quantified using a TaqMan Real-Time PCR assay 
after normalizing to viral production in the HIV-1 mono-
infections as described [28, 35, 67]. Replicative fitness for 
each patient-derived HIV-1 isolate was calculated and 
expressed as a percentage of the replicative fitness of the 
HIV-1B-92US076 control, set as 100%.
Reverse transcription (RT)-PCR amplification of nearly 
full-length HIV-1 genome
Plasma viral RNA was purified from pelleted virus 
particles by centrifuging one milliliter of plasma at 
20,000g  ×  60  min at 4  °C, removing 860  µl of cell-free 
supernatant and resuspending the pellet in the remain-
ing 140  µl, to finally extract viral RNA using QIAamp 
Viral RNA Mini kit (Qiagen; Valencia, CA). Viral RNA 
was reverse-transcribed using AccuScript High Fidelity 
Reverse Transcriptase (Stratagene Agilent; Santa Clara, 
CA) and five previously described antisense external 
primers (Pan-HIV-1-1R [68], 1R, 2R, 3R, and 4R [69]) in 
20 µl reaction mixtures containing 1 mM dNTPs, 10 mM 
DTT and 10 units of RNAse inhibitor. Six overlapping 
fragments, covering almost the entire HIV-1 genome, 
were amplified using a series of external and nested prim-
ers and Phusion High-Fidelity DNA Polymerase (NEB, 
Ipswich, MA) with defined cycling conditions as previ-
ously described [68, 69], i.e., 5′LTR (675 bp; HXB2 coor-
dinates 120 to 794), 5′LTR-gag/p7 (1269 bp; 658 to 1924), 
gag/p24-pol/RT (2327  bp; 1137 to 3463), pol/RT-vif 
(2259 bp; 2976 to 5234), pol/int-env/gp120 (2921 bp; 4602 
to 7522), and env/gp120-3′LTR (2587 bp; 6858 to 9444).
Population (Sanger) sequence analysis
Nested PCR products were purified with the QIAquick 
PCR Purification kit (Qiagen) and sequenced by Sanger 
(population) sequence (GATC Biotech, Constance, 
Germany). Nucleotide sequences were analyzed using 
DNASTAR Lasergene Software Suite v.12.3.1.4 (Madi-
son, WI).
Deep sequencing of nearly full-length HIV-1 genome
All six overlapping HIV-1 fragments, from the seven 
patient-derived plasma samples, were deep sequenced 
using a variation of the DEEPGEN™HIV assay [70]. 
Briefly, the six amplicons were purified (Agencourt 
AMPure XP, Beckman Coulter) and quantified (2100 
Bioanalyzer DNA 7500, Agilent Technologies) prior to 
using the Ion Xpress Fragment Library Kit (Life Tech-
nologies, Carlsbad CA) to construct a multiplexed library 
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for shotgun sequencing on the Ion Personal Genome 
Machine (PGM, Life Technologies). For that, a mixture 
of all six purified DNA amplicons (16 ng each) was ran-
domly fragmented and blunt-ends repaired using the Ion 
Shear Plus Reagent (Life Technologies) followed by DNA 
purification (Agencourt AMPure XP, Beckman Coulter). 
The P1 adapter and one of seven barcodes were ligated 
to the repaired fragment ends prior to DNA purification 
(Agencourt AMPure XP, Beckman Coulter). DNA frag-
ments were then selected by size (i.e., 280–320 bp; Pippin 
Prep, Life Technologies) and each barcoded library, i.e., 
a mixture of all six amplicons per sample, was purified 
(Agencourt AMPure XP, Beckman Coulter) and normal-
ized using the Ion Library Equalizer Kit (Life Technolo-
gies). All seven barcoded DNA libraries, corresponding 
to seven patient-derived amplicons, were pooled in 
equimolar concentrations and templates prepared and 
enriched for sequencing on the Ion Sphere Particles 
(ISPs) using the Ion OneTouch 200 Template Kit v2 (Life 
Technologies) in the Ion OneTouch 2 System (Life Tech-
nologies). Templated ISPs were quantified (Qubit 2.0, 
Life Technologies) and loaded into an Ion 318 Chip (Life 
Technologies) to be sequenced on the Ion PGM using 
the Ion PGM Sequencing 200 Kit v2 (Life Technologies). 
Sequencing run, signal processing and base calling was 
performed with Torrent Analysis Suite version 5.0.4. All 
deep sequencing experiments were performed in the 
CLIA/CAP-accredited University Hospitals Translational 
Laboratory under a good laboratory practice framework.
Read mapping, variant calling, phylogenetic and viral 
diversity analysis
Reads were mapped and aligned (assembled) against the 
HIV-1HXB2 (GenBank: K03455) reference sequence using 
SeqMan NGen (DNASTAR Lasergene Software Suite 
v.12.3.1.4), and the assemblies analyzed using SeqMan 
Pro (DNASTAR Lasergene Software Suite v.12.3.1.4). 
Full-length HIV-1 consensus sequences were generated 
for each patient-derived virus, compared to the cor-
responding population sequences obtained by Sanger 
sequencing, aligned using ClustalW [71] and their phy-
logeny reconstructed using the neighbor-joining statis-
tical method as implemented within MEGA 6.06 [72]. 
Variant calling (i.e., single nucleotide polymorphisms, 
including substitutions, deletions and insertions) and 
their frequencies in the virus population relative to the 
HIV-1HXB2 reference sequence were quantified using 
a proprietary pipeline (Alouani and Quiñones-Mateu, 
unpublished results). Intra-patient HIV-1 quasispe-
cies diversity was determined using near full-length 
HIV-1 genome (or individual genes and coding region 
sequences) based on the p-distance model as described 
for deep sequencing [73].
Statistical analyses
Descriptive results are expressed as mean values, stand-
ard deviations, range, and confidence intervals. As 
described above, differences in the mean of the slope val-
ues for the viral growth kinetics curves were determined 
using a One Way Analysis of Variance test and the differ-
ence from the reference HIV-1NL4-3 virus calculated using 
the Bonferroni’s Multiple Comparison Test. All differ-
ences with a P value of <0.05 were considered statistically 
significant. All statistical analyses were performed using 
GraphPad Prism v.6.0b (GraphPad Software, La Jolla, 
CA) unless otherwise specified. Nucleotide sequences 
of the nearly full-length HIV-1 genomes, both consen-
sus and individual reads, obtained by deep sequencing 
in this study have been submitted to the Los Alamos 




Clinical, virologic, and immunologic characteristics 
of viremic non-progressors, typical and rapid progressor 
patients
As described above, for this study we identified three 
treatment-naïve HIV-infected individuals classified 
as VNPs. At the time of the study, these patients were 
infected with HIV-1 for over 10 years (range 10–17 years), 
maintaining relatively high CD4+ T-cell counts (mean 
472, range 280–814 cells/mm3) with limited decline in 
CD4+ T-cell count (mean slope −0.56, range −0.4 to −0.7 
CD4+ T-cells/month) despite sustained plasma HIV-1 
RNA loads above 4000 copies/ml (mean 5.02 log10, range 
3.61–5.45 copies/ml) during the time these patients were 
monitored prior to this study (range 37–123  months) 
(Table 1; Additional file 1: Figure S1). For comparison, we 
selected three patients classified as typical progressors 
(each infected for at least 10  years, range 12–15  years), 
and one rapid progressor infected for 5 years. Overall, the 
CD4+ T-cell counts for the TPs were similar to that of the 
VNPs (mean 400, range 126–789 cells/mm3) albeit with 
a more marked decline in CD4+ T-cells over time (mean 
slope −10.3, range −8.2 to −13.1 CD4+ T-cells/month). 
Plasma HIV-1 RNA levels for the TPs were similarly high 
(mean 4.45 log10, range 3.89–4.9 copies/ml). As expected, 
the CD4+ T-cell counts from the RP patient were signifi-
cantly lower than those for the VNP and TP individuals 
(mean 57, range 11–124 cells/mm3), declining at a rate 
of −4.7 CD4+ T-cells/month with high plasma HIV-1 
RNA loads (mean 4.49 log10, range 4.09–4.66 copies/ml) 
(Table 1; Additional file 1: Figure S1). The rest of the clini-
cal baseline characteristics showed no significant differ-
ences regarding age, gender distribution, ethnicity, and 
mode of transmission of HIV-1.
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Replicative fitness of HIV-1 isolates from VNP, TP, and RP 
patients
We used two different but complementary approaches 
to quantify the ability of all seven patient-derived HIV-1 
isolates (i.e., 3 VNPs, 3 TPs, and 1 RP) to replicate in vitro 
in the absence of any host selective pressure, including 
antiretroviral drugs. A first glimpse of the replicative fit-
ness of these viruses was obtained using classical viral 
growth kinetics in PBMCs from HIV-seronegative donors 
(Fig.  1a). Statistical analysis of the slope of the growth 
curves showed that the replicative fitness of all three VNP 
viruses was significantly reduced compared to the rep-
licative fitness of the three TP and RP viruses (p < 0.05, 
95% CI, Fig.  1b). Since in  vitro dual infection/growth 
competition experiments are considered the gold stand-
ard method to measure viral fitness [30, 74] we competed 
each one of the seven HIV-1 isolates against two differ-







































































































Fig. 1 Replicative fitness of seven patient‑derived HIV‑1 isolates in the absence of any host selective pressure, including antiretroviral drugs. a 
Seven HIV‑1 isolates from 3 viremic non‑progressor (VNP), 3 typical (TP) and one rapid (RP) progressor patients were evaluated for their ability to 
replicate in peripheral blood mononuclear cells (PBMC). Virus replication was quantified by measuring reverse transcriptase (RT) activity in the 
cell‑free supernatant. b Viral replication slopes were calculated using the slopes between cpm values at days 0 and 4, 0 and 6, 0 and 8, 0 and 11, 
and 0 and 14. All five slope values for each virus were used to calculate the mean, standard deviation, and 10th and 90th percentiles. Differences in 
the mean values were calculated using a One Way Analysis of Variance test and the significance difference from the primary wild‑type HIV‑1B‑92US076 
control isolate calculated using the Bonferroni’s Multiple Comparison Test. c Each patient‑derived HIV‑1 isolate was competed against two different 
non‑subtype B HIV‑1 control strains (HIV‑1A‑92UG029 and HIV‑1AE‑CMU06) in PBMCs and their replicative fitness calculated and expressed as a percent‑
age of the replicative fitness of the reference virus HIV‑1B‑92US076 (set as 100%) as described [28, 35, 66, 67]. Values represent results obtained from 
single growth competition experiments. Viral replication kinetics and growth competitions marked with an asterisk were significantly different to 
the HIV‑1B‑92US076 control (p < 0.05, 95% CI)
Page 7 of 17Weber et al. AIDS Res Ther  (2017) 14:15 
and HIV-1AE-CMU06). Interestingly, all three VNP viruses 
showed a marked decrease in replicative fitness, i.e., 0.1, 
7.5, and 15% relative to that of the primary HIV-1B-92US076 
isolate used as control (Fig. 1c). With the exception of the 
TP-1 virus (9%), the replicative fitness of the other two 
TP viruses was not impaired relative to the fitness of the 
HIV-1B-92US076 control (167 and 118% for TP-2 and TP-3, 
respectively). Finally, the RP virus had a 2.6-fold higher 
replicative fitness than the HIV-1B-92US076 control and, in 
average, was 35-fold more fit to replicate in PBMCs than 
the VNP viruses (Fig. 1c).
Characterization of HIV-1 isolates from VNP, TP, and RP 
individuals: subtyping, drug resistance, and coreceptor 
tropism
To further characterize the HIV-1 isolates, viral RNA 
was used to amplify and sequence near full-length HIV-1 
genomes (HXB2 coordinates 157–99,428) using both 
Sanger and deep sequencing. For deep sequencing, ampli-
cons corresponding to all 7 viruses were multiplexed into 
a single 318c chip (78% loading efficiency of Ion Sphere 
Particles), generating 3,856,115 total quality reads with 
a mean read length of 131 bp (mean range 130–133 bp). 
Although the average sequencing coverage at each 
nucleotide position varied with each sample and HIV-1 
genomic region analyzed (p < 0.0001, one-way ANOVA), 
the mean coverage for each viral sequence ranged from 
2079 reads for the RP virus to 8500 for VNP-3 (Fig. 2a). 
These metrics ensured the minimum coverage of 1000 per 
nucleotide position sequenced required to guarantee the 
detection of a minor variant present at least at 1% of the 
population [75]. As expected, coverage decreases abruptly 
at the ends of the amplicons (e.g., 5′LTR and 3′LTR in 
Fig.  2a); however, we observed an inexplicable decrease 
in coverage around positions 6655–6719 (corresponding 
to variables regions V1 and V2 in gp120, env gene) that 
do not correspond with the end of any of the overlapping 
PCR products covering this genomic region.
The entire HIV-1 genome from all seven viruses 
was classified as subtype B using the Recombinant 
Identification Program from the Los Alamos HIV 
Sequence Database [76] (Table  1; Additional file  2: Fig-
ure S2). We used our proprietary DEEPGEN™HIV Soft-
ware Tool Suite [70] to confirm the absence of mutations 
(at  >1% frequency in the HIV-1 population) associated 
with drug resistance in the protease (PR), reverse tran-
scriptase (RT), and/or integrase (INT) coding regions. 
The same tool was used to determine HIV-1 coreceptor 
tropism based on sequencing reads corresponding to the 
V3 region of gp120. HIV-1 isolates from VNP and TP 
patients were all CCR5-tropic viruses, while the RP indi-
vidual was infected with a dual- or mixed-tropic virus 
(Table 1).
HIV-1 genetic polymorphisms in VNP, TP, and RP viruses
HIV-1 isolates from viremic non-progressor individuals 
showed a clear impairment on their ability to replicate 
in PBMCs in  vitro. Since the fitness decrease was not 
associated with drug resistance mutations, we decided 
to analyze the entire HIV-1 genomes to try to identify 
any particular signature(s) that could be responsible for 
the decrease in replication capacity. First, we scanned all 
seven near full-length HIV-1 genomes searching for pat-
terns in single-nucleotide polymorphisms (SNPs) among 
the three groups of patients. As described in Fig. 2b, we 
observed a higher concentration of SNPs in the variable 
regions of gp120; however, no clear clustering of the VNP 
or TP groups was evident when the SNP patterns of the 
near full-length genomes were analyzed. For example, 
VNP-1 and VNP-3 clustered with TP-3, while VNP-2 was 
closer to TP-1 and TP-2. Similar results were observed 
when SNP patterns were analyzed in each individual 
HIV-1 genomic region, with the exception of gp41 where 
significant clustering of VNP-1 with VNP-3 and all three 
TNP viruses was evident (Additional file 3: Figure S3).
Next, we focused on HIV-1 genetic polymorphisms 
that have been associated with impaired HIV-1 replica-
tive fitness and/or disease progression [11, 31, 32, 40, 
42, 44–62, 77, 78]. We identified a series of SNPs in LTR 
and amino acid substitutions—at different frequencies in 
(See figure on next page.) 
Fig. 2 a Coverage, i.e., number of reads per nucleotide position, obtained by deep sequencing the seven patient‑derived HIV‑1 isolates. Near 
full‑length HIV‑1 genomes were RT‑PCR amplified and deep sequenced as described in “Methods”. The position relative to the HIV‑1 genome of 
the six overlapping amplicons used to amplify and sequence the near full‑length HIV‑1 genomes (HXB2 position 157 to 9428, not counting primer 
sequences) is indicated. b Hierarchical clustering analysis of the single nucleotides polymorphisms (SNPs) was used to group the seven patient‑
derived HIV‑1 isolates by similarity. Dendrograms were calculated using the Euclidean distance and Complete cluster methods with 1000 bootstrap 
iterations as described (http://www.hiv.lanl.gov/content/sequence/HEATMAP/heatmap.html) Bootstrap values >60% are indicated by an asterisk. 
Green and grey blocks indicate the presence or absence of SNPs, respectively, in each HIV‑1 isolate relative to the HIV‑1HXB2 reference. c A Neighbor‑
joining phylogenetic tree was constructed using the near full‑length HIV‑1 consensus sequences generated for each patient‑derived virus (obtained 
from deep sequencing reads) and rooted using the HIV‑1HXB2 sequence (GenBank accession number AF033819). Bootstrap resampling (1000 data 
sets) of the multiple alignment tested the statistical robustness of the tree, with percentage values above 75% indicated by an asterisk.  
s/site substitutions per nucleotide site
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Table 2 HIV-1 genetic polymorphisms identified in this study, which have previously been associated with disease pro-
gression and/or impaired replicative fitness
Positiona Viremic non-progressors (VNP) Typical progressors (TP) Rapid progressor (RP)
VNP-1 VNP-2 VNP-3 TP-1 TP-2 TP-3 RP
LTR













T319A (99%) T319A (100%)
 325–333 329ins (39%)
C333T (11%)
332del (3%) 328ins (1%) G331A (1%)
 346–356 G350A (1%) A348T (11%)
355del (2%)
G350A (3%)
 361–371 G363A (6%)
G364A (7%)
G366A (1%) T32C (9%)
G363A (10%)
















 386–397 C386T (97%) C387G 
(2%)
G389A (30%)
G395A (2%) 380del (1%) G389A (2%) 396ins (99%) 387G (3%) G393A (2%)
 398–409 G399A (7%) 398ins (2%) 403ins (1%)
405ins (3%)
T398A (90%) G409A (8%) G400A (18%)
 427–431 430del (1%), 431del 
(1%)
430del (2%) 430del (9%), 431del 
(1%)
430del (2%) 431del (2%)
 455–515 11SNPs (>1%), 13 
indels (>1%)
8 SNPS, 11 indels 3 SNPs (>1%), 12 
indels (>1%)
3 SNPs (>1%), 5 
indels (>1%)
2 SNPs (>1%), 6 
indels (>1%)
4 SNPs (>1%), 2 
indels (>1%)
5 SNPs (>1%), 3 indels 
(>1%)
gag
 823–825 E12Q (99%)
 988–990 S67A (16%) S67A (3%) S67A (100%)
 1093–1095 D102E (98%) D102E (9%) D102E (73%) D102E (100%)
 1225–1227 A146P (86%)
 1513–1515 T242N (99%)
 1531–1533 G284A (99%) G284A (99%) G284A (99%)
 1954–1956 T389I (99%) T389I (100%)
 2233–2235 E482D (99%)
vif
 5434–5436 R132S (92%)
vpr
 5773–5775 F72S (4%)
 5788–5790 R77Q (99%) R77Q (99%) R77Q (99%) R77Q (99%) R77Q (99%) R77Q (99%)
 5806–5826 Ins (7%)
rev
 8522–8524 Q74H (99%) Q74P (99%) Q74P (75%)
 8612–8614 V104G (99%) V104L (33%)
nef
 9208–9210 T138C (99%)
 8839–8841 T15A (99%) T15A (98%) T15N (100%)
 8950–8952
 9100–9102 H102Y (99%) H102Y (99%) H102W (99%) H102W (99%) H102Y (99%) H102Y (99%) H102Y (100%)
 9340–9342 E182Q (99%) E182V (99%) E182V (99%)
a  Positions in the HIV-1 genome relative to the HIV-1HXB2 (GenBank: K03455) strain reference. Single-nucleotide polymorphisms (SNPs) in the LTR or amino 
substitutions in the HIV-1 coding regions are indicated, including their frequency in the virus population (%) quantified by deep sequencing. For example: A219G 
(18%) in the LTR of the VNP-1 HIV-1 isolate or R77Q (99%) in the vpr gene of the VNP-2 HIV-1 isolate. Indels, insertions and/or deletions
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the virus population—in gag, vif, vpr, rev, and nef genes 
(Table  2). Although no clear pattern of signature muta-
tions was shared among the individual viruses from each 
group, some of the mutations were present only in VNP 
and not in TP or RP sequences, e.g., in the LTR (insertion 
at position 329, G364A, C386T, or G399A), gag (E12Q, 
A146P, T242 N, or E482D), vif (R132S), vpr (F72S), and 
nef (T138C). Interestingly, most of these mutations were 
identified in the VNP-1 isolate, which had the most 
impaired replicative fitness of the group (Fig. 1). In fact, 
the number of HIV-1 genetic polymorphisms previously 
associated with fitness decrease and/or disease progres-
sion was significantly higher in the VNP group com-
pared with the TP and RP viruses (mean 39.3, 21.6, and 
22, respectively, p = 0.036) (Table 2; Fig. 3a). Moreover, 
a strong significant inversed correlation was observed 
between the number of HIV-1 genetic polymorphisms 
in each viral isolate and the HIV-1 replicative fitness val-
ues determined by the slopes of the viral growth curves 
(r  =  −0.956, p  =  0.0007, Pearson coefficient correla-
tion) (Fig. 3b). Although not significant, most likely per-
haps due to the low fitness calculated for the TP-1 virus, 
a similar trend was observed using the replicative fit-
ness values from the growth competition experiments 
(r = −0.547, p = 0.203, Pearson coefficient correlation).
Genetic diversity of VNP, TP, and RP viruses
We used the consensus sequences of the near full-
length HIV-1 genomes generated by deep sequencing 
to construct a neighbor-joining phylogenetic tree. As 
observed in Fig.  2c, the HIV-1 sequences did not clus-
ter together according to their group, i.e., VNP, TP, and 
RP. Identical results were obtained using the population 
sequences generated by Sanger sequencing (data not 
shown). Based on the consensus near full-length HIV-1 
sequences, intra-group genetic distances were not sig-
nificantly different between VNP and TP viruses (0.089 
and 0.096 substitutions/site, respectively, p  =  0.345; 
Maximum Composite Likelihood model). Next we used 
the myriad of reads obtained by deep sequencing to cal-
culate intra-patient HIV-1 population diversity based on 
the p-distance model [73]. Interestingly, the VNP viruses 
showed significantly higher genetic diversity than the TP 
and RP viruses (mean 3.07, 2.52, and 1.93 substitutions/
site, p = 0.009) when the near full-length HIV-1 genomes 
were analyzed (Fig. 4a). Although this trend was consist-
ent across individual HIV-1 genomic regions and genes 
(data not shown), the higher genetic diversity in VNP 
viruses was significant in two regions of the gag gene: p2 
(4.82, 3.09, and 2.76 substitutions/site, p = 0.008) and p6 
(2.9, 1.62, and 1.59 substitutions/site, p = 0.02), and the 
V4 region of gp120 (13.4, 1.54, and 6.39 substitutions/
site, p = 0.018) (Fig. 4a). More importantly, we observed a 
strongly significant negative correlation between genetic 
diversity of the near full-length HIV-1 genomes and the 
replicative fitness values determined by the slopes of 
the viral growth curves (r = −0.878, p = 0.009, Pearson 
coefficient correlation) (Fig.  4b). The same significant 
inverse associations were observed for the two regions of 
the gag gene: p2 (r = −0.833, p =  0.019, Pearson coef-
ficient correlation) and p6 (r = −0.856, p = 0.013, Pear-
son coefficient correlation), and the V4 region of gp120 
(r = −0.825, p =  0.022, Pearson coefficient correlation) 
(Fig. 4b) but not for those regions with no significant dif-
ferences in HIV-1 diversity between the three groups of 
patients. Similar results, i.e., more heterogeneous virus 
population (VNPs) having lower viral replicative fitness 
values, were obtained when replicative fitness was deter-
mined using growth competition experiments (regres-
sion values ranging from −0.791 to −0.867, p  <  0.05, 
Pearson coefficient correlation; data not shown).
Discussion
Since the discovery of HIV-1 as the etiological agent of 
AIDS [79, 80], multitude of studies have attempted to 
understand the differences on HIV-1 disease progres-
sion, particularly host and/or viral factors that could be 
associated with HIV-1 pathogenesis [11, 12, 81]. The 
common (“normal”) inverse correlation between CD4+ 
T-cell count and plasma HIV RNA load usually governs 
HIV-1 pathogenesis, i.e., elevated plasma viremia is typi-
cally accompanied by a decrease in CD4+ T-cells, leading 
to disease progression [2]. Some HIV-infected individu-
als have shown uncommon rates of disease progression 
(slow, non-progressor or elite controllers) but all of them 
have reduced or undetected plasma HIV RNA loads [3, 
4, 42, 82]. On the other hand, a rare group of patients 
termed viremic non-progressors (VNP) seem to resemble 
Simian Immunodeficiency Virus (SIV) infection in sooty 
mangabeys, i.e., active viral replication without (or very 
limited) disease progression [26, 82–84]. Here we iden-
tified three atypically VNP HIV-infected individuals and 
proceeded to study their HIV-1 isolates, focusing on rep-
licative fitness and viral genomic analysis to try to under-
stand the maintenance of stable CD4+ T-cell counts 
despite persistence viremia for more than 10 years, in the 
absence of antiretroviral treatment.
As described above, viremic non-progressor (control-
ler) patients do not progress to AIDS, maintaining high 
CD4+ T-cell counts with HIV-1 replication for many 
years [5–7, 85]. The three VNP individuals described 
in this study had been infected with HIV-1 for at least 
10 years at the time the blood sample was taken, with sta-
ble CD4+ T-cell counts and high plasma HIV RNA loads. 
When compared with three typical (TP) and one rapid 
progressor (RP) patients, the number of CD4+ T-cells 
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barely declined in the VNPs over this period of time, 
similar to what have been described for other adult and 
children VNPs [43, 82–84, 86]. No other significant dif-
ferences were observed among the VNP and TP patients, 
including plasma viral load levels and basic virus charac-
teristics such as HIV-1 subtype (all clade B) and corecep-
tor tropism (all CCR5-tropic viruses).
Most studies involving the characterization of viremic 
non-progressor (controller) patients have focused in 
host factors to try to understand their odd HIV-1 dis-
ease progression profile. For example, the presence of the 
HLA-B*27 allele was associated with the VNP phenotype 
[43], while a higher frequency of the protective single 
nucleotide polymorphism −35 CC in the HLA-C gene 
was found in VNP patients [5]. Preferential Gag-spe-
cific CD8+ T cell responses have also been observed in 
viremic controllers [84] and limited infection of CD4+ 
central memory cells [8], perhaps related to low CCR5 
expression on these cells [86], seem to be associated with 
lack of disease progression in VNPs. Limited deregula-
tion of a series of interferon-stimulated genes correlat-
ing with time to disease progression was also identified 
in VNPs [85]. However, and similar to the absence of 
immune activation during natural SIV infection in sooty 
mangabeys [27, 87, 88], healthy CD4+ T cell counts 
despite detectable viremia seem to be common in most 
viremic non-progressor patients [86]. Yet, just a limited 
number of studies have analyzed HIV-1 strains infecting 
VNPs [6, 43].
Here we showed that the replicative fitness of all three 
VNP-derived HIV-1 isolates was impaired compared to 
the fitness of the viruses obtained from the TP and RP 
patients. We and others have reported that HIV-1 rep-
licative fitness is associated with disease progression 
[28–30, 42], that is, viruses with decreased replication 
capacity influence the natural history of HIV-1 infec-
tion, correlating with diminished viral burden and HIV-1 
pathogenesis. Viruses from long-term non-progressor 
[28], slow progressor [41, 42] and elite controller [37, 40, 
42] patients have been shown to have impaired replica-
tion capacity; however, the fitness of viruses from VNP 
individuals have not been extensively described. Choud-
hary et  al. [6] showed that HIV-1 isolates derived from 
VNP were as cytopathic as viruses isolated from typi-
cal progressor patients. On the other hand, O’Connell 
et  al. [43] observed a slight decrease in the fitness of a 
virus from a VNP patient, transmitted from a chronic 
progressor partner, but failed to identify any amino acid 
substitution(s) potentially responsible for this phenotype.
Reduced HIV-1 replicative fitness is usually the con-
sequence of changes in the viral quasispecies following 
the evasion of key selective pressures, e.g., host immune 
response and/or antiretroviral treatment [30, 31]. These 
changes are accompanied by single or multiple mutations 
in the targeted HIV-1 genomic region, deviating the virus 
population from the wild-type quasispecies distribution 
and impairing their ability to replicate efficiently com-
pared to the original virus [89, 90]. The effect of a mul-
titude of drug resistance mutations (in the pol gene) in 
viral replicative fitness have been amply described [30, 
74]. A number of CTL escape mutations have been iden-
tified in HIV and SIV that carry a concomitant replicative 
fitness cost [46, 91, 92], including HIV-1 mutant variants 
escaping Gag-specific CD8+ T cell responses—like those 



















































Fig. 3 a Comparison of the number of HIV‑1 genetic polymorphisms 
in the near full‑length HIV‑1 genome that have been associated with 
impaired HIV‑1 replicative fitness and/or disease progression [11, 31, 
32, 40, 42, 44–62, 77, 78] among the three groups of patients, i.e., VNP, 
RP, and TP. Unpaired t test was used to assess the statistical signifi‑
cance between VNP and TP patients. A detailed list of the mutations 
is included in Table 2. b Pearson correlation coefficient was used to 
determine the strength of association between the number of HIV‑1 
genetic polymorphisms and the HIV‑1 replicative fitness calculated 
by viral growth kinetics analysis (viral replication slope) described 
in Fig. 1. r correlation coefficient, p two‑tailed p value. Dotted lines 
represent 95% confidence intervals
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replicative fitness [40]. Other studies have shown how 
multiple mutations and/or deletions in the LTR and 
all HIV-1 coding regions have a range of effects on the 
ability of the virus to replicate (virus attenuation) [11, 
31, 32, 40, 42, 44–62, 78]. Here we used deep sequenc-
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Fig. 4 a Comparison of intra‑patient HIV‑1 population diversity, based on the p‑distance model [73], among the three groups of patients, i.e., 
VNP, RP, and TP. Unpaired t test was used to assess the statistical significance between VNP and TP patients. Only those HIV‑1 regions significantly 
different, i.e., near full‑length HIV‑1 genome, Gag p2, Gag p6, and Gp120 V4, are included. b Pearson correlation coefficient was used to determine 
the strength of association between intra‑patient HIV‑1 population diversity values (p‑distance) and the HIV‑1 replicative fitness calculated by viral 
growth kinetics analysis (viral replication slope) described in Fig. 1. r correlation coefficient, p two‑tailed p value. Dotted lines represent 95% confi‑
dence intervals
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all VNP-derived viruses, and compared them with the 
sequences from the TP- and RP-derived viral genomes. 
Despite identifying a series of SNPs in different genomic 
regions, some of them previously associated with a 
reduction in replicative fitness and/or disease progres-
sion [11, 31, 32, 40, 42, 44–62, 77, 78], no clear pattern of 
signature mutations was detected in the viruses from the 
VNPs that could explain the impairment in replication 
capacity. Interestingly, it was the number of these HIV-1 
genetic polymorphisms that correlated significantly with 
the replicative fitness of each HIV-1 isolate. In fact, it is 
reasonable to think that viruses with a higher number of 
critical SNPs have a more marked decrease in replicative 
fitness, similar to what has been described for multidrug-
resistant HIV-1 variants carrying multiple mutations in 
the protease, reverse transcriptase and/or integrase cod-
ing regions [30, 74]. These results were corroborated by 
calculating intra-patient HIV-1 population diversity, 
i.e., the highly replication impaired VNP viruses had a 
more complex virus quasispecies population, most likely 
as a consequence of trying to evade the host immune 
response [93], which was highlighted by the significant 
correlation between replicative fitness and HIV-1 genetic 
diversity in highly immunogenic regions such as Gag and 
Gp120 [31, 42, 92]. We and others have described simi-
lar results where drug resistant HIV-1 variants with more 
heterogeneous virus population had lower viral replica-
tive fitness [94, 95]. It is possible that impaired (less repli-
cation competent) HIV-1 strains are capable to ascertain 
a limited host immune response in VNPs, enough to 
maintain high levels of viremia, resulting in viral evolu-
tion but limiting host immune activation that could exac-
erbate HIV disease, i.e., decrease CD4+ T-cell counts. It 
is also possible that the preferential replication of HIV-1 
in effector memory T cells, and preservation of central 
memory T cells, in VNPs [8] could result in greater virus 
production per HIV-infected cell. All interesting possi-
bilities to be addressed in further studies.
Although prevalence of elite controllers seems to be 
less than 1% of the HIV-infected population [96, 97], a 
recent study involving over 13,000 HIV-infected individ-
uals identified 271 viremic controllers for a 2.03% preva-
lence [82]. Interestingly, viremic pediatric nonprogressor 
patients with high CD4+ T cell counts seem to be more 
common than adults VNP individuals [86]. Is it possible 
that VNP patients are more common than what we origi-
nally thought? If so, what can we learn from these individ-
uals that could help monitor and control HIV-1 infection 
in less fortunate patients? Several studies have pointed 
to high levels of immune activation as the major cause of 
HIV-1 pathogenesis [24, 98] and low immune activation 
seems to be—at least in part- responsible for the lack of 
disease progression in VNP individuals [86]. Moreover, 
the VNP-like phenotype during natural SIV infections 
in sooty mangabeys is definitely not related to a low rate 
of viral production nor an impairment on replicative fit-
ness of the virus [25, 87]. However, we cannot rule out 
that original infection with less replication-competent 
viruses (therefore seeding HIV-1 reservoirs with replica-
tion impaired variants) could contribute to the decrease 
in immune activation, leading to the viremic non-pro-
gressor phenotype in these patients. Here we observed 
that all three VNP patients carried HIV-1 isolates with 
decreased replicative fitness compared to typical and 
rapid progressor individuals, and that accumulation of 
single-nucleotide polymorphisms (mutations) across the 
HIV-1 genome may be contributing to the overall fit-
ness impairment. Therefore, it is possible that similar to 
the phenomenon observed in patients with a discordant 
response to antiretroviral therapy, i.e., high CD4+ cell 
counts with detectable plasma HIV-1 RNA load [99, 100], 
reduced viral replicative fitness could be contributing to 
late disease progression in untreated viremic controller 
individuals. Additional studies involving host immunol-
ogy and genetics, together with more detailed analysis 
of the HIV-1 strains infecting VNP patients, are neces-
sary to better understand HIV-1 pathogenesis, includ-
ing approaches to prevent HIV-1 disease and potentially 
eliminate HIV reservoirs.
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